CA - Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript

2024-05-02 12:03:11 ET

Aurinia Pharmaceuticals Inc. (AUPH)

Q1 2024 Earnings Conference Call

May 02, 2024 08:30 AM ET

Company Participants

Andrea Christopher - Head, Corporate Communications & Investor Relations

Peter Greenleaf - Chief Executive Officer

Joe Miller - Chief Financial Officer

Greg Keenan - Chief Medical Officer

Conference Call Participants

Farzin Haque - Jefferies

Stacy Ku - TD Cowen

Joseph Schwartz - Leerink Partners

Ed Arce - H.C. Wainwright

David Martin - Bloom Burton

Presentation

Operator

Greetings, and welcome to the Aurinia Pharmaceuticals First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to turn the conference over to Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Please go ahead, Andrea.

Andrea Christopher

Thank you, operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Aurinia's Chief Executive Officer; Joe Miller, our Chief Financial Officer; and Dr. Greg Keenan, our Chief Medical Officer.

Today, we will review and discuss Aurinia's 2024 first quarter financial and operational results as communicated in the company's press release issued this morning. The company also filed its quarterly financial statements on Form 10-Q this morning. For more information, please refer to Aurinia's filings with the US Securities and Exchange Commission and applicable Canadian securities authorities, which are also available on Aurinia's website at auriniapharma.com.

During today's call, Aurinia may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. For a discussion of factors that could affect Aurinia's future financial results and business, please refer to the disclosures in Aurinia's press release, its quarterly report on Form 10-Q and its annual report on Form 10-K and all of its recent filings with the US Securities and Exchange Commission and Canadian securities authorities....

For further details see: